. But there's little agreement on how to finance their development, and the situation is deteriorating.Antibiotics are a bad business, at least based on a current pharma model that's predicated on volume sales.
That's driven most incumbents out of the business, bankrupted some pure play developers, and scared off many venture capitalists. But today it did announce a new deal: Plugging around $9 million into BioVersys, a Swiss company in the clinic with a product aimed at certain lung and bloodstream infections that kill up to 100,000 people per year. It also has early-stage programs, including one aimed at multidrug-resistant tuberculosis.
Resumimos esta notícia para que você possa lê-la rapidamente. Se você se interessou pela notícia, pode ler o texto completo aqui. Consulte Mais informação: